Methods of treating cancer with HDAC inhibitors
The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
1 - 178 . (canceled)
179 . A method of treating leukemia in a subject, said method comprising the step of orally administering to the subject three times daily at a dose of 250 mg for 14 days followed by 1 week without dose administration of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:
as the active ingredient, wherein administration of SAHA is effective to treat leukemia in said subject.
180 . The method of claim 179 wherein the leukemia is Acute Myeloid Leukemia (AML).
181 . The method of claim 179 wherein the leukemia is Acute Lymphocytic Leukemia (ALL).
182 . The method of claim 179 wherein the leukemia is Chronic Lymphocytic Leukemia (CLL).
183 . The method of claim 179 wherein the leukemia is Chronic Myeloid Leukemia (CML).
184 . The method of claim 179 wherein the leukemia is Hairy Cell Leukemia (HCL).
185 . The method of claim 179 wherein the leukemia is Chronic Myelomonocytic Leukemia (CMML).
186 . A method of treating leukemia in a subject, said method comprising the step of orally administering to the subject three times daily at a dose of 200 mg for 14 days followed by 1 week without dose administration of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:
as the active ingredient, wherein administration of SAHA is effective to treat leukemia in said subject.
187 . The method of claim 186 wherein the leukemia is Acute Myeloid Leukemia (AML).
188 . The method of claim 186 wherein the leukemia is Acute Lymphocytic Leukemia (ALL).
189 . The method of claim 186 wherein the leukemia is Chronic Lymphocytic Leukemia (CLL).
190 . The method of claim 186 wherein the leukemia is Chronic Myeloid Leukemia (CML).
191 . The method of claim 186 wherein the leukemia is Hairy Cell Leukemia (HCL).
192 . The method of claim 186 wherein the leukemia is Chronic Myelomonocytic Leukemia (CMML).